Protagonist Therapeutics vs Vir Biotechnology
Vir Biotechnology is the larger business, with $68.6m of revenue in fiscal 2025 against $46.0m for Protagonist Therapeutics (1.5 times as much). Vir Biotechnology grew faster (-7.6% against -89.4%). Protagonist Therapeutics kept more of each dollar of sales as profit: a net margin of -282.8% against -638.9%. Protagonist Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Protagonist TherapeuticsPTGX, 2025 | Vir BiotechnologyVIR, 2025 |
|---|---|---|
| Revenue | $46.0m | $68.6m |
| Revenue growth | -89.4% | -7.6% |
| Net income | −$130m | −$438m |
| Operating margin | -343.6% | -699.2% |
| Net margin | -282.8% | -638.9% |
| Return on equity | -20.2% | -45.7% |
| Free cash flow | $56.1m | −$397m |
| Cash | $128m | $232m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 132 | 367 |
| Market value | $9.14bn | $1.91bn |
| Price vs our value range | Above our value range | — |
| Moat score | 14 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 37 sales | 0 buys, 35 sales |